临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2014年
4期
27-29
,共3页
黄俊%任颖%胡国平%周先勇%朱斌
黃俊%任穎%鬍國平%週先勇%硃斌
황준%임영%호국평%주선용%주빈
难治性精神分裂症%帕利哌酮缓释片%氯氮平%阳性与阴性症状量表%功能大体评定量表
難治性精神分裂癥%帕利哌酮緩釋片%氯氮平%暘性與陰性癥狀量錶%功能大體評定量錶
난치성정신분렬증%파리고동완석편%록담평%양성여음성증상량표%공능대체평정량표
TRS%paliperidone ER%clozepine%PANSS%GAF
目的:探讨帕利哌酮缓释片与氯氮平治疗难治性精神分裂症的临床疗效和安全性。方法将60例难治性精神分裂症患者随机分为两组,每组30例,研究组口服帕利哌酮缓释片治疗,对照组口服氯氮平治疗,观察12周。治疗前后采用阳性与阴性症状量表、功能大体评定量表评定临床疗效,副反应量表评定不良反应。结果治疗第12周末研究组总有效率为56.7%,对照组为60.0%,两组比较差异无显著性(χ2=0.07,P>0.05)。治疗后两组功能大体评定量表评分均呈持续性升高,研究组治疗第8周、12周末较对照组升高更显著( P<0.05或0.01)。研究组不良反应发生率为36.7%,对照组为73.3%,研究组显著低于对照组(χ2=8.15,P<0.01)。结论帕利哌酮缓释片与氯氮平治疗难治性精神分裂症疗效显著且相当,但帕利哌酮缓释片能显著改善患者的社会功能,安全性更高,更有利于提高患者的治疗依从性。
目的:探討帕利哌酮緩釋片與氯氮平治療難治性精神分裂癥的臨床療效和安全性。方法將60例難治性精神分裂癥患者隨機分為兩組,每組30例,研究組口服帕利哌酮緩釋片治療,對照組口服氯氮平治療,觀察12週。治療前後採用暘性與陰性癥狀量錶、功能大體評定量錶評定臨床療效,副反應量錶評定不良反應。結果治療第12週末研究組總有效率為56.7%,對照組為60.0%,兩組比較差異無顯著性(χ2=0.07,P>0.05)。治療後兩組功能大體評定量錶評分均呈持續性升高,研究組治療第8週、12週末較對照組升高更顯著( P<0.05或0.01)。研究組不良反應髮生率為36.7%,對照組為73.3%,研究組顯著低于對照組(χ2=8.15,P<0.01)。結論帕利哌酮緩釋片與氯氮平治療難治性精神分裂癥療效顯著且相噹,但帕利哌酮緩釋片能顯著改善患者的社會功能,安全性更高,更有利于提高患者的治療依從性。
목적:탐토파리고동완석편여록담평치료난치성정신분렬증적림상료효화안전성。방법장60례난치성정신분렬증환자수궤분위량조,매조30례,연구조구복파리고동완석편치료,대조조구복록담평치료,관찰12주。치료전후채용양성여음성증상량표、공능대체평정량표평정림상료효,부반응량표평정불량반응。결과치료제12주말연구조총유효솔위56.7%,대조조위60.0%,량조비교차이무현저성(χ2=0.07,P>0.05)。치료후량조공능대체평정량표평분균정지속성승고,연구조치료제8주、12주말교대조조승고경현저( P<0.05혹0.01)。연구조불량반응발생솔위36.7%,대조조위73.3%,연구조현저저우대조조(χ2=8.15,P<0.01)。결론파리고동완석편여록담평치료난치성정신분렬증료효현저차상당,단파리고동완석편능현저개선환자적사회공능,안전성경고,경유리우제고환자적치료의종성。
Objective To explore the efficacy and safety of paliperidone extended-release tablets (paliperi-done ER) vs .clozepine in the treatment of treatment-resistant schizophrenia (TRS) .Methods Sixty TRS patients were randomly assigned to two groups of 30 ones each ,research group took orally paliperidone ER and control did clozepine for 12 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Function (GAF) and adverse reactions with the Treatment E-mergent Symptom Scale (TESS) before and after treatment .Results At the end of the 12th week total ef-fective rate was respectively 56 .7% in research and 60 .0% in control group ,which showed no significant difference (χ2 =0 .07 ,P> 0 .05) .After treatment GAF scores of both groups heightened continuously , those did more significantly at the end of the 8th and 12th week in research than in control group (P<0 .05 or 0 .01) .The incidence of adverse reaction was respectively 36 .7% in research and 73 .3% in control group ,the former was significantly lower than the latter (χ2 =8 .15 ,P<0 .01) .Conclusion Paliperidone ER has an evident effect equivalent to clozapine in TRS ,but the former could improve patients’ social functions ,has higher safety ,and is more beneficial to improving patients’ compliance .